A 12-year-old girl with severe catecholamine-induced dilated cardiomyopathy due to a pheochromocytoma was treated for 7 months with phenoxybenzamine and MPT to decrease plasma catecholamine levels.
Case Report (n=1)
Medical therapy with phenoxybenzamine and MPT can be used to manage catecholamine-induced dilated cardiomyopathy in a child with pheochromocytoma when surgery is initially too hazardous.
PATIENTS with a severe, dilated cardiomyopathy with congestive heart failure have a poor prognosis unless a correctable cause can be identified. Even when a cause is found, the degree of reversibility of myocardial injury is uncertain.1 We describe a 12-year-old child with a pheochromocytoma who had a dilated cardiomyopathy and congestive heart failure due to excessive production of catecholamines by the tumor. Because her poor clinical state made surgery too hazardous, she was treated for seven months with the a-adrenergic-receptor antagonist phenoxybenzamine and the tyrosine hydroxylase inhibitor α-methylpara-tyrosine (MPT) to decrease her plasma catecholamine levels. With increasing doses of MPT, . . .
Imperato‐McGinley et al. (1987) conducted a case report in Catecholamine-induced dilated cardiomyopathy and congestive heart failure (n=1). Phenoxybenzamine and α-methylpara-tyrosine (MPT) was evaluated. A 12-year-old girl with severe catecholamine-induced dilated cardiomyopathy due to a pheochromocytoma was treated for 7 months with phenoxybenzamine and MPT to decrease plasma catecholamine levels.